ArticleAddiction (Abingdon, England)2021
Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Article in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.The Australian and New Zealand journal of psychiatry · 2024Pooled it
- Article
- Use of pharmacotherapy for alcohol use disorders and the risk of unemployment: a cohort study of 77 503 workers in Sweden.Occupational and environmental medicine · 2026Article
- Antidepressants, relapse-prevention medications and both combined to reduce alcohol-related hospitalizations in individuals with severe alcohol use disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Socio-economic differences in the effectiveness of pharmacotherapy use in alcohol use disorder: A cohort study of 148 626 individuals in Sweden.Addiction (Abingdon, England) · 2026Article
- The Impact of Psychiatric Interventions on Mortality in Patients With Alcohol-Related Diseases.Psychiatry investigation · 2025Article
- Utilisation of alcohol-related treatment after a first alcohol use disorder diagnosis in Hamburg, Germany.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Pharmacotherapy for Alcohol Use Disorder Is Underutilized Among Commercially Insured Adults With Alcohol-Associated Liver Disease.Gastro hep advances · 2025Article
- Observational
- Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis.BMJ open gastroenterology · 2024Article
- Alcoholic cardiomyopathy: an update.European heart journal · 2024Review
- Clustering care pathways of people with alcohol dependence using a data linkage of routine data in Bremen, Germany.BMC medicine · 2024Article
- Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge.JAMA network open · 2024Article
- The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.Current medicinal chemistry · 2024Review
- Psychotropic medication use pre and post-diagnosis of cluster B personality disorder: a Quebec's health services register cohort.Frontiers in psychiatry · 2023Article
- The use of medications approved for alcohol use disorders in Italy.Frontiers in public health · 2023Article
- Estimating the prevalence of alcohol-related disorders and treatment utilization in Bremen 2016/2017 through routine data linkage.Frontiers in psychiatry · 2023Article
- Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study.Basic & clinical pharmacology & toxicology · 2022Article
- Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis.Journal of general internal medicine · 2022Article
- Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.JAMA network open · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPharmacotherapy for alcohol use disorder (AUD) is recommendable, but under-used, possibly due to deficient knowledge of medications. This study aimed to investigate the real-world effectiveness of approved pharmacological treatments (disulfiram, acamprosate, naltrexone and nalmefene) of AUD.
designA nation-wide, register-based cohort study.
settingSweden.
participantsAll residents aged 16-64 years living in Sweden with registered first-time treatment contact due to AUD from July 2006 to December 2016 (n = 125 556, 62.5% men) were identified from nation-wide registers. MEASUREMENTS: The main outcome was hospitalization due to AUD. The secondary outcomes were hospitalization due to any cause, alcohol-related somatic causes, as well as work disability (sickness absence or disability pension), and death. Mortality was analysed with between-individual analysis using a traditional multivariate-adjusted Cox hazards regression model. Recurrent outcomes, such as hospitalization-based events and work disability, were analysed with within-individual analyses to eliminate selection bias.
findingsNaltrexone combined with acamprosate [hazard ratio (HR) = 0.74; 95% confidence interval (CI) = 0.61-0.89], combined with disulfiram (HR = 0.76, 95% CI = 0.60-0.96) and as monotherapy (HR = 0.89, 95% CI = 0.81-0.97) was associated with a significantly lower risk of AUD-hospitalization compared with no use of AUD medication. Similar results were found for risk of hospitalization due to any cause. Benzodiazepine use and acamprosate monotherapy were associated with an increased risk of AUD-hospitalization (HR = 1.18, 95% CI = 1.14-1.22 and HR = 1.10, 95% CI = 1.04-1.17, respectively). No statistically significant effects were found for work disability or mortality.
conclusionsNaltrexone as monotherapy and when combined with disulfiram and acamprosate appears to be associated with lower risk of hospitalization due to any and alcohol-related causes, compared with no use of alcohol use disorder (AUD) medication. Acamprosate monotherapy and benzodiazepine use appear to be associated with increased risk of AUD-associated hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.